Lecanemab treatment stopped tangle accumulation over the course of the study, according to data presented at the 2024 AD/PD conference (Mar 2024 conference news). This occurred regardless of baseline tau load. In February 2024, Eisai began post-marketing tracking of lecanemab safety in Japan, where it was approved in late 2023.

2022年10月12日 · Lecanemab likely demonstrates a class effect for drugs that robustly remove amyloid. This is wonderful news for our patients in the long term. In the short term, lecanemab's results indicate that aducanumab's FDA approval last year was a good move, and Medicare's NCA was a terrible mistake. Given the recent data, Medicare should cover ...

2024年10月22日 · Lecanemab also binds to fibrils, which comprise amyloid plaques, but with a 10-fold greater affinity for protofibrils relative to fibrils (Soderberg et al., 2023). Fertan et al. describe the binding profile using a SiMoA assay, mimicking aggregates. Lecanemab showed strongest binding to soluble Aβ42 aggregates.

As lecanemab use ramps up, clinicians expect demand to overwhelm the staff at most memory clinics. At WashU’s Knight Alzheimer Disease Research Center—one of the larger centers in the country—the staff comprises 12 physicians and four physician assistants or nurse practitioners.

Lecanemab was first approved in the U.S. two years ago, and has been covered by insurance for a year and a half (Jan 2023 news; Jul 2023 news). Since then, its use has crept up slowly while clinics put new procedures in place to diagnose, infuse, and monitor AD patients ( …

2021年11月26日 · In head-to-head comparisons, lecanemab bound small protofibrils of 75-300 kD 10 times as strongly as did gantenerumab, and 100 times more than aducanumab. For larger protofibrils of 300-500 kDa, lecanemab bound 25 times as strongly as aducanumab. If lecanemab mostly targets protofibrils, how does it clear fibrillar plaque?

Unlike the initially broad label granted aducanumab, lecanemab’s FDA label restricts use to people with evidence of amyloid plaque buildup and mild cognitive impairment or mild dementia. This is the same population studied in the clinical trials, and is estimated to comprise 1 million people in the U.S., or about 20 percent of those with AD ...

2022年12月9日 · Lecanemab had similar effects in all subgroups examined, though men appeared to benefit more than women, older people more than younger, and APOE4 non-carriers more than carriers. [Courtesy of Eisai.] Van Dyck also showed results from several sensitivity analyses that suggested the findings were not caused by confounding factors.

2022年7月7日 · Lecanemab, aka BAN2401, follows the path established by aducanumab, which received accelerated approval last year (Jun 2021 news). On the heels of that approval, the FDA granted lecanemab breakthrough therapy status, a designation that speeds the regulatory process and allows companies to submit data as they acquire it.

2022年12月9日 · Lecanemab, previously known as BAN2401, was developed as an antibody generated against a unique antigen, Ab protofibrils (Lannfelt et al., 2014) The basis of this antigen was recognized by Dr. Lars Lannfelt, given the effects seen from the “Arctic mutation” in APP that he identified in Sweden. Patients with this mutation developed AD ...